The company Alzinova AB from GU Innovation, Gothenburg, Sweden, conducts research and development of a long acting drug for treatment and prevention of Alzheimer´s disease. The company has a patented technology, a proprietary AβCC peptide™, that enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer’s disease research.